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Abstract
Purpose: High serum prolactin concentrations have been associated with adverse health 
outcomes in some but not all studies. This study aimed to examine the morbidity and all-
cause mortality associated with hyperprolactinaemia.
Methods: A population-based matched cohort study in Tayside (Scotland, UK) from 1988 
to 2014 was performed. Record-linkage technology was used to identify patients with 
hyperprolactinaemia that were compared to an age–sex-matched cohort of patients free 
of hyperprolactinaemia. The number of deaths and incident admissions with diabetes 
mellitus, cardiovascular disease, cancer, breast cancer, bone fractures and infectious 
conditions were compared by the survival analysis.
Results: Patients with hyperprolactinaemia related to pituitary tumours had no increased 
risk of diabetes, cardiovascular disease, bone fractures, all-cause cancer or breast cancer. 
Whilst no increased mortality was observed in patients with pituitary microadenomas 
(HR = 1.65, 95% CI: 0.79–3.44), other subgroups including those with pituitary 
macroadenomas and drug-induced and idiopathic hyperprolactinaemia demonstrated 
an increased risk of death. Individuals with drug-induced hyperprolactinaemia also 
demonstrated increased risks of diabetes, cardiovascular disease, infectious disease and 
bone fracture. However, these increased risks were not associated with the degree of 
serum prolactin elevation (Ptrend > 0.3). No increased risk of cancer was observed in any 
subgroup.
Conclusions: No excess morbidity was observed in patients with raised prolactin due 
to pituitary tumours. Although the increased morbidity and mortality associated with 
defined patient subgroups are unlikely to be directly related to the elevation in serum 
prolactin, hyperprolactinaemia might act as a biomarker for the presence of some 
increased disease risk in these patients.
Introduction
Hyperprolactinaemia is a common condition in 
endocrine practice (1). It may occur in men and women 
at any age, and its prevalence and incidence depend on 
the study population. Its epidemiology in the general 
population has been recently established by the Prolactin 
Epidemiology, Audit and Research Study (PROLEARS)  – 
a population-based cohort study in Tayside (Scotland, 
UK) (2). This study showed an overall prevalence of 
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hyperprolactinaemia (i.e. prolactin greater than 1000 U/L) 
over a period of 20 years of 1 per 1000 of the population 
and the age–sex-adjusted incidence rates were 21.5 per 
100,000 person-years for women and 6.4 per 100,000 
person-years for men. The highest incidence rates were 
found in women aged 25–44 years.
Hyperprolactinaemia can be physiological, 
pathological or iatrogenic, and the causes of non-
physiological hyperprolactinaemia include pituitary 
disorders, drugs (most commonly antipsychotic agents) 
and hypothyroidism; aside from these, idiopathic 
hyperprolactinaemia is not uncommon (3). In the 
PROLEARS study, the commonest cause was drug-
induced (45.9%), followed by pituitary disorders 
(25.4%) and idiopathic cases (15%) (2). Regardless of 
aetiology, hyperprolactinaemia may cause symptoms 
related to excess prolactin (e.g. galactorrhoea) or due to 
suppression of the hypothalamic–pituitary–gonadal axis 
(e.g. amenorrhea, infertility and erectile dysfunction). In 
addition, high concentrations of serum prolactin have 
been inconsistently related to several adverse health 
outcomes including cardiovascular disease, cancer, 
osteoporosis, autoimmune conditions and all-cause 
mortality (1).
There are little useful data on hyperprolactinaemia 
and cardiovascular endpoints. Controversy exists as 
to whether hyperprolactinaemia may be associated 
with heart valve disease (including that related to the 
use of dopamine agonist therapy), cardiovascular risk 
factors or cardiovascular mortality (4, 5, 6, 7). Results 
from epidemiologic studies that have examined the 
relationship between prolactin and all-cause cancer 
or breast cancer have also given inconsistent results 
(8, 9, 10, 11, 12, 13, 14, 15, 16). Similarly, there are no 
consistent correlations reported between prolactin levels 
and bone loss or autoimmune diseases; thus, the clinical 
significance of hyperprolactinaemia in these patients 
remains unclear (17, 18, 19, 20, 21, 22, 23, 24, 25, 26). 
There are little available data on mortality associated with 
hyperprolactinaemia, although one study suggested that 
high serum prolactin levels might be associated with an 
increased risk of death (6). These results give grounds for 
a hypothesis that there may be subgroups of patients with 
hyperprolactinaemia at variable health risks.
The Centre for Endocrine Epidemiology in Tayside 
(Scotland, UK) has undertaken data linkage to report on 
incidence and prevalence of hyperprolactinaemia (2). We 
aimed to use the same data linkage to examine morbidity 
and mortality associated with hyperprolactinaemia, as 
well as the relative contribution of the respective causes 
of hyperprolactinaemia.
Subjects and methods
A population-based retrospective matched cohort 
study was performed among patients ever registered 
with a general practitioner in Tayside, a well-defined 
geographical region within Scotland (UK), with a mainly 
Caucasian population of 400,000 people. All patients 
are issued a unique patient identification number 
(Community Health Index) which facilitates the linkage 
of all electronic medical records and official registers. The 
biochemistry database was linked anonymously to other 
databases by the Health Informatics Centre Services/Farr 
Institute of Scotland at the University of Dundee (http://
www.dundee.ac.uk/hic) as previously described (2). These 
included demographic records (gender, birth, migration 
and deprivation based on patient’s full postcode – 
Scottish Index of Multiple Deprivation – SIMD), Scottish 
Morbidity Records – SMR (maternity admissions, hospital 
admissions, surgical procedures and cancer registration), 
Scottish Care Information-Diabetes Collaboration – 
SCIDC database (data from primary care and diabetes 
clinics on diabetes mellitus), prescriptions dispensed and 
the General Registrar Office – GRO records on patient 
deaths. Magnetic Resonance Imaging (MRI) reports were 
also accessed and linked for identifying pituitary tumours. 
The International Classification of Diseases (ICD) 9–10th 
revision codes were used in the SMR to identify hospital 
inpatient and cancer events, and prescriptions were 
identified by means of the British National Formulary 
(BNF) codes (Table 1). To ensure data quality, SMR data 
are routinely subjected to a set of validation rules by 
the Information Services Division (ISD – NHS National 
Services Scotland) to evaluate and ensure that these 
datasets are accurate, consistent and comparable across 
time and between sources (27).
Hyperprolactinaemia and comparison 
cohort definition
The identification of individuals with hyperprolactinaemia 
among those with at least one measurement of a serum 
prolactin level taken was as previously reported (2). Any 
patient with a serum prolactin measurement greater than 
1000 U/L (47.2 ng/mL) and/or three or more prescriptions 
of specific dopamine agonists (BNF 6.7.1: cabergoline, 
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bromocriptine and/or quinagolide) during the follow-up 
period was considered as exposed, with subsequent alloca-
tion to one of the four cause-related subgroups as follows: 
1. Pituitary disorder. Patients were selected if they had 
at least one serum prolactin measurement greater 
than 5000 U/L (235.8 ng/mL), and/or three or more 
prescriptions of specific dopamine agonists, hospital 
admissions related to pituitary disorder (ICD10: C751, 
E22, E23), pituitary surgery (OPCS-4: B01, B02, B04) or 
a mass on pituitary MRI.
2. Drug-induced. Patients were selected if they had 
a record of being prescribed drug(s) known to 
elevate prolactin levels within 6  months before and 
1  month after the assessment of serum prolactin 
measurement, and did not fit into pituitary disorder 
group. Any prescription of antipsychotics (BNF: 4.2.1, 
4.2.2), tricyclics and related antidepressants (BNF: 
4.3.1), serotonin re-uptake inhibitors (BNF: 4.3.3), 
dopamine antagonists (BNF: 4.6), opioids and drugs 
used in opioid dependence (BNF: 4.7.2, 4.10.3), H2 
antagonists (BNF: 1.3.1), methyldopa (in BNF: 2.5.2) 
and verapamil (in BNF: 2.6.2) was extracted from the 
database containing prescriptions dispensed from all 
community pharmacies in Tayside.
3. Macroprolactin. Patients were selected if they had a 
presence of macroprolactin identified without any 
other explanation.
4. Hypothyroidism. Patients were selected if they had 
a thyroid-stimulating hormone (TSH) serum level 
>6 U/L (0.28 ng/mL) at some time without any other 
explanation.
5. Idiopathic. Patients were selected if remained 
unclassified.
The pituitary disorder group was further stratified into 
micro- (≤1 cm) and macroadenoma (>1 cm) subgroups based 
on available MRI reports. All patients who were pregnant or 
possibly lactating at the time of assay (i.e. within 9 months 
before and 12  months after the delivery date) were 
excluded (unless they had raised prolactin measurements 
out with this time window) together with those patients 
with hyperprolactinaemia related to macroprolactin.
For each patient with hyperprolactinaemia, the 
patients’ register was used to identify five patients matched 
by age (±6 months) and gender for comparison, that were 
free of hyperprolactinaemia (i.e. unexposed). Baseline 
data at the date of entry into the study were collected 
for all patients. The numbers of patients with defined 
clinical outcomes of interest before and after entering 
the study were also identified. The period of follow-up 
for the analysis was defined from 1988 to 2014. Each 
eligible patient was followed up until either occurrence 
of outcome of interest or end of study (i.e. moving out of 
health area, death or 30 May 2014).
Statistical analysis
The mean and standard deviation or the median and the 
interquartile range of the data were calculated to describe 
continuous variables. ANOVA and chi-square tests were 
used to compare means and frequencies among subgroups 
of patients, respectively. Non-parametric methods were 
used where appropriate.
Table 1 Codes used to identify hospital admissions, cancer registration and prescriptions of interest.
Description   
Admissions (SMR) ICD-9 codes ICD-10 codes
Bone fractures 800–829, E887 M484, M80, M81, S02, S12, S22, S32, S42, S52, S62, 
S72, S82, S92, T02, T08, T10, T12, T142
Osteoporotic bone fractures 733.1, 805.4, 805.5, 806.4, 806.5, 813, 820, 821 M80, S32, S52, S72
Cardiovascular disease 410–429 I20–I25, I44, I45, I47–I50
Cancer 140–209 C00–C97; D00–D09
Breast cancer 174, 175, 198.81, 233.0 C50, D05
Infectious conditions 001–136, 460–466, 480–487, 680–686 A00–A99, B00–B99, G00–G02, G04–G07, J00–J22, 
L00–L08
Autoimmune conditions 242.0, 245.8, 255.4, 258.1, 579.0, 340, 358, 
571.4, 571.6, 695.4, 710.2, 710.3, 710.4
 D51.0, E27.1, E27.2, E31.0, E03.5, E03.8, E05.0, 
E06.3, G70.0, K74.3, K90.0, M32-M35
Prescriptions BNF codes  
Prednisolone within 6.3.2  
Bisphosphonates 6.6.2  
Dopamine agonists 6.7.1  
HRT 7.3.1  
BNF, British National Formulary; HRT, Oestrogen containing hormone replacement therapy; ICD, International Classification of Diseases (ICD-9 = Ninth 
Revision codes, ICD-10 = Tenth Revision codes); SMR, Scottish Morbidity Records.
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Survival analysis was performed to follow-up 
patients and Cox proportional hazards’ models using 
the robust variance estimator were used to explore the 
relationship between exposure to hyperprolactinaemia 
and clinical outcomes. A separate analysis estimating 
the hazard ratios (HRs) with 95% confidence intervals 
(CI) associated with hyperprolactinaemia was performed 
for each outcome. Log-rank tests of equality across 
strata were obtained for all categorical covariates, and 
univariate Cox models were fitted for the continuous 
covariates to explore whether or not to also include 
them in the multivariate model. Categorical covariates 
were included as dummy variables. Adjusted models 
were stratified by the matched sets of subjects on 
age and gender (i.e.  matched analysis). A test of the 
proportional hazards was performed for each covariate 
and globally using a formal significance test based on 
Schoenfeld residuals and by plotting log–log plots (28). 
Model specification was evaluated using goodness-of-
fit diagnostics by computing Harrell’s C coefficient 
(28). Exposure was coded as binary (i.e. ever vs never 
had hyperprolactinaemia) as well as dummy variables 
to consider six levels of exposure (i.e. never had 
hyperprolactinaemia, ever had hyperprolactinaemia 
related to a pituitary microadenoma, pituitary 
macroadenoma, drug-induced, secondary to hypo-
thyroidism or idiopathic causes). Quintiles of the 
serum prolactin concentration were used to break the 
range of the exposure into categories and look for 
trends in the category-specific HRs (i.e. dose–response 
or trend analysis). Data were entered into a STATA/MP 
version 14.0 software package (StataCorp, USA) for 
statistical analysis and determination of statistical 
significance (P < 0.05).
Outcomes
All outcomes were incident and coded as binary. Patients 
with prevalent outcomes of interest at baseline were 
excluded from the survival analysis of that particular 
outcome. Outcomes were death, diabetes mellitus, 
bone fractures, non-fatal cardiovascular disease, cancer, 
autoimmune conditions and infectious conditions. 
Limiting this study to only incident outcomes avoided 
bias from missing data on prior events (i.e. left 
censoring) (29).
For some outcomes being modelled, the following 
covariates were also considered for inclusion: history of 
medication used, history of renal impairment (serum 
Table 2 Description of patients at first diagnosis of hyperprolactinaemia and their comparison cohort.
Characteristic Hyperprolactinaemia (n = 1204) Comparison cohort (n = 5888) P
n (%)    
Gender- female 943 (78.3) 4602 (78.2) =0.901
SIMD quintile    
 1 most deprived 309 (26.4) 1162 (20.5)  
 2 230 (19.7) 995 (17.6)  
 3 184 (15.7) 926 (16.4)  
 4 306 (26.2) 1634 (28.9)  
 5 most affluent 141 (12.1) 940 (16.3) <0.001
Diabetes Mellitus 70 (5.8) 204 (3.5) <0.001
Non-fatal Cardiovascular disease 62 (5.2) 183 (3.1) <0.001
Cancer 101 (8.4) 411 (6.9) =0.085
Bone fractures 76 (6.3) 264 (4.5) =0.007
Infectious conditions 198 (16.5) 588 (9.9) <0.001
Renal impairment 79 (6.5) 378 (6.4) =0.855
Medication use    
 Bisphosphonate 16 (1.3) 62 (1.1) =0.403
 Prednisolone 93 (7.7) 282 (4.8) <0.001
 HRT 205 (17.0) 1270 (21.6) <0.001
Mean (s.d.)    
Age (years)* 39.5 (16.5) 38.7 (15.6) =0.123
Serum prolactin (U/L) 1514 (1177–2382) 193 (143–255) <0.001
Serum TSH (U/L) ϕ 2.2 (1.4–3.9) 2.4 (1.6–3.5) =0.003
(*) Age at study entry (ϕ) Maximum serum concentration: median (interquartile range).
HRT, Oestrogen containing hormone replacement therapy; SIMD, Scottish Index of Multiple Deprivation; TSH, Thyroid-stimulating hormone.
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creatinine level >150/120 µmol/L for men/ women, 
respectively) and social deprivation index – SIMD.
Ethical approval
All analyses were performed on anonymised datasets. 
The study was approved by the Tayside Medical Ethics 
Committee and data protection by the Tayside Caldicott 
Guardians, and conducted in accordance with the 
Declaration of Helsinki. The funders had no role in design, 
analysis, interpretation or writing of the manuscript.
Results
We identified 1204 patients with hyperprolactinaemia 
(331 related to a pituitary disorder, 598 drug-induced, 79 
secondary to hypothyroidism and 196 idiopathic causes) 
and 5888 age- and sex-matched patients as a comparison 
Table 3 Estimates of hazard ratios for hyperprolactinaemia on having several clinical outcomes by related cause of 
hyperprolactinaemia.
   Unadjusted Adjusted
Outcome Time at risk (years) Events n HR 95% CI HR 95% CI
Diabetes mellitus 64,068 334     
 Microadenoma   0.885 0.461–1.699 1.203 0.643–2.250
 Macroadenoma   1.925 0.710–5.220 1.419 0.542–3.714
 Drug-induced   2.032 1.408–2.932* 1.638 1.154–2.325*
 Hypothyroidism   0.884 0.364–2.148 1.431 0.555–3.689
 Idiopathic   0.716 0.352–1.456 0.898 0.452–1.785
Non-fatal Cardiovascular diseasea 64,805 238     
 Microadenoma   0.698 0.287–1.700 1.383 0.543–3.519
 Macroadenoma   2.641 0.977–7.137 2.183 0.863–5.524
 Drug-induced   1.758 1.128–2.739* 1.854 1.171–2.937*
 Hypothyroidism   1.544 0.669–3.560 2.071 0.846–5.064
 Idiopathic   0.651 0.266–1.591 1.222 0.506–2.949
Cancer 61,714 440     
 Microadenoma   0.877 0.492–1.563 1.447 0.821–2.549
 Macroadenoma   2.087 0.919–4.738 1.580 0.628–3.976
 Drug-induced   1.370 0.956–1.962 0.977 0.668–1.427
 Hypothyroidism   0.945 0.447–1.998 1.487 0.746–2.963
 Idiopathic   0.614 0.317–1.189 0.811 0.413-1.593
Bone fracturesb 63,627 285     
 Microadenoma   0.847 0.401–1.791 1.435 0.636–3.238
 Macroadenoma   0.534 0.075–3.802 0.664 0.120–3.667
 Drug-induced   2.733 1.932–3.865* 2.087 1.478–2.948*
 Hypothyroidism   1.103 0.443–2.746 1.219 0.491–3.025
 Idiopathic   0.911 0.449–1.849 1.190 0.571–2.481
Infectious conditionsc 59,231 623     
 Microadenoma   0.619 0.339–1.132 0.727 0.420–1.259
 Macroadenoma   1.849 0.929–3.679 1.245 0.602–2.576
 Drug-induced   2.276 1.771–2.925* 1.899 1.479–2.440*
 Hypothyroidism   1.339 0.772–2.323 1.296 0.740–2.269
 Idiopathic   0.622 0.348–1.111 0.848 0.482–1.491
Deathd 65,579 465    
 Microadenoma   0.886 0.471–1.669 1.658 0.798–3.446
 Macroadenoma   6.207 3.694–10.427* 2.815 1.420–5.579*
 Drug-induced   4.164 3.276–5.293* 3.358 2.568–4.392*
 Hypothyroidism   2.680 1.606–4.472* 5.125 2.457–10.691*
 Idiopathic   1.954 1.294–2.951* 3.728 2.306–6.027*
Adjusted models were stratified by the matched sets of subjects on age and gender. (*) P < 0.05.
aAdjusted also for history of diabetes mellitus and renal impairment.
bAdjusted also for history of bisphosphonates use, prednisolone use and renal impairment.
cAdjusted also for history of prednisolone use.
dAdjusted also for history of non-fatal cardiovascular disease, renal impairment and a Scottish index of multiple deprivation.
HR, Hazard ratio.
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cohort. The total follow-up was 70,836 person-years with 
a mean follow-up of 10.1 years (s.d. 6.9) and a maximum 
follow-up of 25.7 years.
The distribution of patients by age and gender was 
nearly identical between the two cohorts as expected 
in a matched design (Table 2). The majority of patients 
were women (78%) and mean age was 39  years. SIMD 
was unavailable for 2.8 and 4% of the exposed and 
unexposed cohorts, respectively. SIMD and serum TSH 
levels were different between the two cohorts; patients 
with hyperprolactinaemia were more deprived and had 
lower TSH values at baseline. Averaged maximum serum 
concentration of prolactin was much higher in patients 
with hyperprolactinaemia by definition (1514 U/L  vs 
193 U/L). The exposed cohort was more likely to 
have diabetes (80% type 2), cardiovascular disease, 
bone fractures or infectious conditions and has been 
prescribed prednisolone as compared to the unexposed 
cohort at baseline, but was less likely to be prescribed 
oestrogen-containing hormone replacement therapy. The 
pituitary disorder group was further stratified into 196 
microadenoma and 54 macroadenoma cases based upon 
linked MRI reports where available.
We evaluated the morbidity risks associated with 
hyperprolactinaemia by the respective patient subgroup 
(Table  3). No increased morbidity was observed in any 
of the patient subgroups except those with drug-induced 
hyperprolactinaemia where there was an increased risk of 
diabetes mellitus (HR = 1.63, 95% CI: 1.15–2.32), non-fatal 
cardiovascular disease (HR = 1.85, 95% CI:  1.17–2.93), 
bone fractures (HR = 2.08, 95% CI: 1.47–2.94) and 
infectious conditions (HR =1.89, 95% CI: 1.48–2.44) 
after adjustment for potential confounding baseline 
characteristics. However, when the increased risks of 
these adverse health outcomes were analysed by quintiles 
of prolactin concentration, no significant dose–response 
relationship was observed (Fig. 1A, B and C). No increased 
risk of all-cause cancer or breast cancer (HR = 0.98, 96% 
CI: 0.56–1.71) was observed in the drug-induced group or 
any of the other groups.
Finally, we examined mortality risk by subgroup. No 
increased mortality was observed in patients with pituitary 
microadenomas. In contrast, increased mortality risks 
were observed in each of the other subgroups including 
those with pituitary macroadenomas and those with 
drug-induced hyperprolactinaemia (Table  3). However, 
when we evaluated mortality outcomes by quintiles of 
prolactin concentration, no significant trend was observed 
either (Fig. 1D) indicating that any relationship between 
mortality-raised prolactin is unlikely to be causal.
Discussion
This study demonstrated that patients with 
hyperprolactinaemia due to pituitary microadenomas and 
macroadenomas had no increased risk of cardiovascular 
disease, diabetes, cancer, bone fractures or infectious 
diseases. The most common treatment for these 
conditions is the use of dopamine agonists, and the 
Figure 1
Estimated HRs (± 95% CI) for several clinical 
outcomes in patients with hyperprolactinaemia 
according to serum prolactin levels. Footnote: 
Quintiles of maximum serum prolactin levels 
(<1130, 1131–1360, 1361–1762, 1763–2637, 
>2637 U/L). Hazard ratios calculated using Cox 
proportional hazards’ models. (A) Diabetes 
mellitus model adjusted for age and gender. 
Wald linear test of parameter estimates Chi2 
(3) = 3.59, P = 0.30. (B) Non-fatal cardiovascular 
disease model adjusted for age, gender, history of 
diabetes mellitus and renal impairment; Wald 
linear test Chi2 (3) = 0.93, P = 0.81. (C) Bone 
fractures model adjusted for history of 
bisphosphonates use, prednisolone use and renal 
impairment; Wald linear test Chi2 (3) = 0.73, 
P = 0.86. (D) Mortality model adjusted for age, 
gender, history of non-fatal cardiovascular 
disease, renal impairment and a Scottish index of 
multiple deprivation; Wald linear test 
Chi2 (3) = 3.26, P = 0.35.
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lack of association with adverse endpoints is reassuring. 
Patients with drug-induced hyperprolactinaemia had 
an increased risk of diabetes, cardiovascular disease, 
bone fractures and infectious diseases but not of cancer. 
We performed a further dose–response analysis (Fig.  1), 
suggesting that the association between these endpoints 
and serum prolactin is unlikely to be causal. Of note, 
antipsychotic agents, which are the commonest group of 
drugs that cause hyperprolactinaemia, are known to cause 
weight gain which increases the risk of both diabetes and 
cardiovascular disease. Our studies indicate that these 
adverse health outcomes are unlikely to be directly related 
to the increased serum prolactin concentration.
Patients with pituitary microadenomas had no 
increased mortality, which is reassuring as this is 
the common type of pituitary tumour associated 
with hyperprolactinaemia, whilst patients with 
hyperprolactinaemia due to macroadenomas, drug-
induced hyperprolactinaemia and hypothyroidism all 
had increased mortality. However, we subsequently 
demonstrated an absence of any dose–response 
relationship between the extent of serum prolactin 
elevation and the risk of death, once again indicating that 
the association with this outcome is unlikely to be direct 
(i.e. not due to the raised serum prolactin per se). In the 
current analysis, we have insufficient data to explore the 
possible reasons for the increased risk of death, although 
premature mortality has been reported in patients with 
pituitary macroadenomas. For example, other hormonal 
deficiencies as a result of hypopituitarism or excessive 
steroid replacement in the past may contribute to adverse 
health outcomes (30). Similarly, poorly controlled 
hypothyroidism, to the level that causes secondary 
hyperprolactinaemia, has been shown to cause increased 
death rates (31), whilst the increased death risk for 
people with drug-induced hyperprolactinaemia may 
be due to the higher risk of diabetes and cardiovascular 
disease associated with antipsychotic drugs. Increased 
risk of suicide could also be expected for people on anti-
psychotropic drugs. In addition, it is possible that patients 
with mental health disorders taking antipsychotic drugs 
are more likely to have adverse lifestyle factors including 
smoking and/or physical inactivity, not captured in the 
current study.
It is very reassuring to note that across all the groups 
of hyperprolactinaemic patients, none were associated 
with an increased risk of overall cancer or breast cancer. 
The prospective Nurses’ Health Study (NHS and NHSII) 
and a meta-analysis of 7 observational studies reported an 
increased risk of breast cancer of borderline significance, 
with the latter showing a relative risk of 1.16 (95% CI: 
1.04–1.29) for the highest vs lowest levels of serum 
prolactin (16, 8). A small increased overall cancer risk 
(HR = 1.31, 95% CI: 1.02–1.68) was reported by Berinder 
et  al. from a population-based cohort study of 969 
patients with visible pituitary adenomas and/or diagnosis 
of hyperprolactinaemia followed for 14  years but no 
increased risk of breast cancer was observed (12). However, 
several large case-controlled and population-based cohort 
studies have failed to show any increased risk of breast 
cancer (9, 11, 14). As in our study, Berinder et al. was not 
able to adjust for confounders regarding cancer, but we 
were able to adjust for oestrogen containing hormone 
replacement therapy regarding breast cancer (12). Our 
large population-based study adds further support to the 
lack of association between raised serum prolactin and 
breast cancer.
Excluding drug-induced causes, none of the 
hyperprolactinaemia groups were associated with the 
risk of diabetes. This is notable, as both negative and 
positive associations between serum prolactin and 
diabetes risk have been reported. For example, one 
study demonstrated a negative association between 
serum prolactin concentrations and risk of diabetes in 
women (HR = 0.48, 95% CI: 0.26–0.90) (32), whilst others 
indicated an increased risk of diabetes in men with 
increasing prolactin concentrations within the reference 
range (OR = 1.70, 95% CI: 1.04–2.78) (7). Furthermore, 
in vivo studies have demonstrated that prolactin is a 
key regulator of β-cell proliferation in rodents and that 
lactogenic hormones are responsible for expansion of 
β-cell mass during pregnancy (33). Thus, the absence of 
an overt association between hyperprolactinaemia and 
diabetes risk in the current clinical study is both important 
and reassuring. Furthermore, our dose–response analysis 
indicates that the increased risk of diabetes in the drug-
induced hyperprolactinaemia group is unlikely to be 
directly related to serum prolactin concentrations.
High concentrations of serum prolactin have 
been related to decreased bone mineral density and 
an increased risk of bone fragility (25, 17, 18). A 13% 
increased rate of fractures was reported in patients 
prescribed both prolactin-increasing and non-prolactin-
increasing antipsychotics (19). The present study showed 
an increased risk of fractures, but only in the drug-
induced hyperprolactinaemia subgroup. Unfortunately, 
we were unable to correct for confounding factors such 
as physical activity, diet and smoking. Patients with 
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hyperprolactinaemia secondary to pituitary tumours 
will usually have been treated with dopamine agonists, 
with the aim of lowering serum prolactin, which is likely 
to negate any increased fracture risk associated with 
hyperprolactinaemia. In contrast, many patients with 
drug-induced hyperprolactinaemia will not have had 
their serum prolactin concentrations lowered, thereby 
remaining at risk of hypogonadism unless treated with 
appropriate oestrogen or testosterone replacement, and 
this might explain the increased incidence of fractures. 
Similarly, this might account for the increased risk of 
infectious disease in the drug-induced patient group, 
possibly through an effect on immunomodulation (23).
Limitations of this study include that although results 
were adjusted for several potential confounders, it was not 
possible to adjust for body mass or smoking which may 
have varied between certain groups (e.g. those on anti-
psychotropic drugs for mental health disorders). Patients 
considered as exposed in the study included those with a 
serum prolactin greater than 1000 U/L and although this 
cut-off may have missed some patients with more modest 
clinically relevant prolactin elevations, it excluded 
patients with transiently raised levels and/or those with 
stress-induced hyperprolactinaemia. We do not have data 
on the total duration of exposure to medication in the 
drug-induced group and patients were classified in this 
group if they had a record of being prescribed a drug(s) 
known to elevate prolactin levels within 6 months before 
and 1  month after the assessment of serum prolactin 
measurement. It is possible that some of the pituitary 
macroadenomas may have been due to the stalk effect 
of non-functioning pituitary macroadenomas, and such 
patients may have been hypopituitary taking other 
hormonal replacements such as corticosteroids. Although 
data on morbidity relate mainly to hospital admissions 
and would have missed outpatient events, the prescription 
data included all outpatient prescriptions and the 
impact of missing values is considered low. This was an 
observational study and therefore causal interpretations 
of risk estimates should be taken carefully.
In conclusion, people with hyperprolactinaemia 
due to pituitary tumours did not have an increased 
risk of adverse health outcomes including diabetes, 
cardiovascular disease, bone fractures, infections or 
cancer. Similarly, individuals with microprolactinomas 
did not display increased mortality. In contrast, an 
increased risk of death was observed in all other groups 
of patients with hyperprolactinaemia, including those 
with pituitary macroadenomas, although this association 
was unlikely to be directly related to the elevation in 
serum prolactin concentration. A number of adverse 
health outcomes were observed in individuals with drug-
induced hyperprolactinaemia, including cardiovascular 
disease, diabetes and fracture, although again this was 
unlikely to be causal. Importantly, no increased risk of all-
cause cancer or breast cancer was observed in any of the 
hyperprolactinemic subgroups.
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